Stock Forecast

  Daxor Corporation ( DXR) Stock. Should you Buy or Sell?    $ 12.80

-0.06 (-0.47 %)



Daxor Corporation Analysis

Updated on 10-09-2022
Symbol DXR
Price $12.80
Beta -0.944
Volume Avg. $2.71 thousand
Market Cap $51.75 M
52 Week Range $9.52 - $14.55


Daxor Corporation opened the day at $12.80 which is -0.47 % on yesterday's close. Daxor Corporation has a 52 week high of $14.55 and 52 week low of $9.52, which is a difference of $5.03. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $51.75 M and total net profit is $5821183 which means the company is trading at 8.89 times profit to market capitalization. Theoretically, if you were to buy Daxor Corporation for $51.75 M, it would take 15 years to get your money back. Daxor Corporation are in the Medical Instruments & Supplies space which will have a sweet spot and industry standard for net profit multiples.



Price Chart


1 D | All


Financials




Daxor Corporation Stock Forecast - Is Daxor Corporation a Buy or Sell?


DCF ScoreStrong Buy
ROE ScoreStrong Sell
ROA ScoreSell
DE ScoreNeutral
PE ScoreStrong Sell
PB ScoreStrong Buy
Overall RecommendationNeutral

Growth and Value


PE Ratio 12.431
Dividend Yiel 0.000
Net Profit Margin -6.122


Valuing Daxor Corporation


Price Book Value Ratio 2.354 Price To Book Ratio 2.354
Price To Sales Ratio 71.179 Price Earnings Ratio -11.626


How liquid is Daxor Corporation


Current Ratio 0.000
Quick Ratio 0.000


Debt


Debt Ratio 0.153 Debt Equity Ratio 0.181
Long Term Debt To Capitalization 0.125 Total Debt To Capitalization 0.000



Latest news about Daxor Corporation


Daxor Corporation to Attend the H.C. Wainwright 24th Annual Global Investment Conference

Oak Ridge, TN, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will attend the H.C. Wainwright 24th Annual Global Investment Conference being held on September 12 – 14, 2022 at the Lotte New York Palace.

Date : 06/09/2022

Daxor Corporation (DXR) Q2 2022 Earnings Call Transcript

Daxor Corporation (NASDAQ:DXR ) Q2 2022 Earnings Conference Call August 25, 2022 4:30 PM ET Company Participants Scott Gordon - President and Co-Founder of CORE IR Michael Feldschuh - CEO & President Robert Michel - CFO Conference Call Participants Anthony Vendetti - Maxim Group Edward Wu - Ascendiant Capital Michael Samuels - Berthel Fisher Operator Good afternoon, and welcome to the Daxor Corporation First Half 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in listen-only mode.

Date : 26/08/2022

Date : 24/08/2022

Daxor Corporation to Present at the H.C. Wainwright & Company Global Investment Conference

NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that President and CEO Michael Feldschuh will present at the H.C. Wainwright Global Life Investment Hybrid Conference which is being held from May 23-26th at the Fontainebleau Miami Beach Hotel, Miami FL.

Date : 12/05/2022

Daxor Corporation to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

Oak Ridge, TN, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that CEO and President Michael Feldschuh will present a corporate overview at the H.C. Wainwright BioConnect 2022 Virtual Conference, which is taking place on January 10 – 13, 2022.

Date : 06/01/2022





About Daxor Corporation


CEO : Mr. Michael Feldschuh
Sector : Healthcare
Industry : Medical Instruments & Supplies

Website : https://www.daxor.com

Exchange : NASDAQ Capital Market

Description :

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.


My Newsletter

Sign Up For Updates & Newsletters